KPV 10 mg

Compound profile

KPV: compound profile, literature landscape and handling notes

Where KPV came from

The origin of KPV is a subtraction rather than a synthesis program. Alpha-melanocyte-stimulating hormone is one of the peptides cleaved from pro-opiomelanocortin, the same precursor protein that yields adrenocorticotropic hormone and the endorphins. Alpha-MSH is a thirteen-residue, C-terminally amidated peptide, and the classical literature on it is pigmentary: it was characterized as the signal that drives melanin production, and its name records that history.

What redirected the field was the observation, accumulated across several decades of work, that alpha-MSH also suppressed inflammatory readouts in systems that had nothing to do with pigment cells. That raised the structural question that produced KPV. If a single thirteen-residue peptide carries two apparently unrelated activities, are they carried by the same part of the molecule? The way to find out is to cut the peptide up and test the pieces, and that is what was done. The His-Phe-Arg-Trp core in the middle of the sequence had already been identified as the message segment that melanocortin receptors read, so removing it should abolish pigmentary signaling. The reported result was that the C-terminal fragment, and ultimately the last three residues, retained a substantial part of the anti-inflammatory readouts while the pigmentary readouts went away with the core.

That is the whole conceptual content of KPV, and it is worth stating plainly because it is routinely inverted in secondary writing. KPV is not a small version of alpha-MSH. It is the part of alpha-MSH that is left when the receptor-binding motif is deleted, and its interest lies precisely in what it lacks. A researcher planning work on this molecule should treat the alpha-MSH literature as background context for the hypothesis rather than as evidence about the tripeptide, because the entire premise of the compound is that the two behave differently. The corpus that actually concerns KPV as a distinct entity is much younger and much smaller than the corpus that concerns its parent.

Reading the structure of KPV

The exact sequence string, formula and mass for this listing are printed in the specification table further down this page, taken from the product record rather than restated here. What is worth doing is reading the three residues, because with only three there is nowhere for a structural feature to hide and each one is doing identifiable work.

Lysine contributes the only ionizable side chain of consequence: a primary amine that is protonated across the entire practical pH range, giving the peptide a fixed positive charge and a large part of its aqueous solubility. Proline is the conformational element. Its side chain closes back onto the backbone nitrogen, which removes an amide hydrogen, restricts the backbone dihedral angles the residue can adopt, and makes the preceding peptide bond capable of populating both cis and trans states at equilibrium rather than sitting overwhelmingly trans as ordinary peptide bonds do. In a tripeptide that single feature dominates the conformational description: the molecule is not a flexible string, it is a short, partially rigid unit with two accessible backbone geometries. Valine supplies a branched hydrophobic terminus, which is a notable choice given how polar the rest of the molecule is.

The point that deserves more honesty than it usually gets is the C-terminus. Two distinct molecules travel under the name KPV in the literature: the free acid, terminating in a carboxylate, and the amide, terminating in a primary amide. They are not the same compound. They differ in net charge at neutral pH, in hydrogen-bonding capacity at that end of the molecule, and in mass by a small increment. Alpha-MSH itself is C-terminally amidated, so the amide is the form that genuinely reproduces the parent peptide's terminus, and papers that intend to model the alpha-MSH C-terminus generally specify the amide. A great deal of vendor and secondary material does not specify at all, which means that a reader comparing two sources may be comparing two molecules without knowing it. Which form a given listing is should be read from the specification table further down this page rather than assumed from the three-letter name.

The target and the pathway in more detail

This is the section where an honest entry has to say that the mechanism is unsettled, because it is, and because the confident mechanistic paragraphs that circulate about KPV are mostly imported from alpha-MSH.

The first candidate is melanocortin receptor involvement, and the structural argument against it is strong. The melanocortin receptors read the His-Phe-Arg-Trp message sequence; that motif is not present in a lysine-proline-valine tripeptide. Reported KPV activity in cells that do not express the relevant receptors, and in preparations where receptor antagonism does not abolish the readout, has been used to argue for a receptor-independent route. The literature is not unanimous on this, and some work continues to invoke melanocortin receptor participation, particularly MC1R, in specific cell types. The reasonable position is that receptor-independent action is the better-supported reading of the published data while receptor participation has not been formally excluded in every system.

The second candidate is a direct intracellular effect on inflammatory transcription, specifically interference with nuclear translocation of NF-kappaB. Several reports describe the peptide reducing NF-kappaB pathway activation in stimulated epithelial and immune cells, which is a readout compatible with the peptide acting inside the cell rather than at its surface.

That immediately raises the question of how a peptide gets in, and the third element of the story is the most interesting one in this catalog. PepT1 is a proton-coupled oligopeptide transporter that moves di- and tripeptides across the apical membrane of intestinal epithelial cells. Its substrate specificity is essentially defined by peptides of exactly the length KPV is, and its expression is reported to increase in inflamed intestinal tissue. That combination supplies a plausible and testable route by which a tripeptide could reach an intracellular target, and it also predicts tissue selectivity, since the transporter is not uniformly expressed. Almost every other compound in this catalog acts at a cell-surface receptor; KPV is the one where a transporter is a central part of the proposed mechanism. Whether transport is required for activity, or merely one route among several, is not settled, and studies that manipulate transporter expression are the ones worth reading closely.

What the published literature on KPV actually measures

The KPV literature is small, and its small size is the most important thing to know about it before reading any single paper. This is not a compound with thousands of independent citations; it is a compound with a modest corpus in which individual papers carry disproportionate weight.

The largest component is cell culture. Intestinal epithelial cell lines stimulated with an inflammatory agonist, then assayed for cytokine output, for NF-kappaB pathway activation by reporter or by translocation imaging, and for barrier readouts such as transepithelial electrical resistance, are the standard preparation. Immune cell lines, including monocyte and macrophage lines, appear in a similar role. Keratinocyte and fibroblast work appears in the dermatological arm. These experiments measure changes in inflammatory signaling in a dish under defined stimulation, which is a narrow and well-defined claim, and they are the source of most of the mechanistic reasoning in the previous section.

The second component is rodent colitis models, most often chemically induced colitis in mice, with readouts including histological scoring, tissue cytokine measurement and body weight as a proxy for disease severity. These are the experiments most often cited when the compound is discussed, and they are also the ones where the transporter argument gets its supporting evidence, because the intestinal epithelium is where PepT1 lives. A subset of this work compares delivery routes and formulations, which is mechanistically informative rather than translational.

The third and thinnest component is dermatological, largely in vitro and in explant preparations, looking at inflammatory readouts in skin-derived cells. It is worth noting what this arm does not contain: given that the defining property of KPV is the loss of pigmentary activity, one might expect a substantial body of work explicitly testing pigment-cell readouts with the tripeptide as a negative control. That comparison is made far less often than the strength of the claim would warrant, and much of the confidence that KPV lacks pigmentary activity rests on the structural argument about the missing message motif rather than on a broad set of direct measurements.

What is essentially absent is a controlled clinical literature. There is no body of registered interventional trial reporting for KPV comparable even to the modest records behind other compounds in this catalog. Anyone citing KPV should describe the evidence base as preclinical, because that is a complete and accurate description of it, and should distinguish sharply in their own writing between a result obtained with the tripeptide and a result obtained with alpha-MSH.

Where the KPV literature is thin or frequently misread

Four specific problems recur in how the KPV record is read, and all four are avoidable.

The first is mechanistic overconfidence. The mechanism is not settled. Receptor-independent action, intracellular interference with NF-kappaB translocation, and transporter-mediated entry are three claims of different evidential strength that are frequently presented as one coherent established pathway. They are not equally supported, and none of them is closed. Writing that states the mechanism flatly is overstating the record.

The second is the amide-versus-acid ambiguity, which quietly contaminates cross-paper comparison. If one report used the amide and another used the free acid, and neither says so in the abstract, a reader comparing their numbers is comparing two molecules. This is a mundane problem rather than a deep one, but it is a real reason why apparently conflicting results in a small corpus may not conflict at all.

The third is the weight-of-a-single-paper problem. In a corpus this size, one well-cited study becomes the factual basis for a large fraction of everything written afterward, and secondary sources cite each other rather than returning to the primary report. Before relying on a specific claim about KPV, it is worth tracing it back and checking whether it rests on one experiment in one cell line from one group, because often it does.

The fourth is the largest and it is a marketing artifact rather than a scientific one. KPV is routinely promoted using claims drawn wholesale from the far bigger alpha-MSH literature, which inverts the entire premise of the compound. The reason KPV exists as a distinct research object is that it is not alpha-MSH and does not do everything alpha-MSH does. Importing the parent's evidence to support the fragment discards the only interesting fact about the fragment. If a claim about KPV is sourced to a paper whose methods used alpha-MSH, it is a claim about alpha-MSH.

How KPV behaves in solution

A tripeptide sits at the small end of what behaves in a recognizably peptide-like way, and several of the habits researchers bring from working with thirty-residue peptides mislead here.

Solubility is not the problem it is elsewhere in this catalog. With a permanently charged lysine side chain and only one hydrophobic residue, KPV dissolves readily in water and in ordinary aqueous buffers, and the aggregation and self-association behavior that dominates acylated or amphiphilic peptides is not a significant feature. There is no hydrophobic face to bury and no secondary structure to nucleate on.

The arithmetic point is more practically useful and it catches people out. Molar amount per unit mass scales inversely with molecular weight, so a milligram of a tripeptide contains far more moles than a milligram of a thirty-residue peptide. A researcher who has internalized a feel for what a given mass corresponds to in molar terms from working with larger peptides will underestimate the molar content here by roughly an order of magnitude. Molar concentrations should be calculated from the mass in the specification table rather than estimated from habit.

Two smaller behaviors are worth recording. Proline cis-trans isomerization interconverts on a timescale that can be comparable to a chromatographic separation, which is a solution-phase property with an analytical consequence noted below. And short peptides are lost to surfaces and to filtration more readily than their size suggests: with so little molecule, a proportionally small absolute loss to a container wall, a syringe filter membrane or a pipette tip is a large fractional loss, and filter membranes are not all equally inert toward small charged solutes. Pre-rinsing a filter, minimizing transfer steps and using low-binding labware all help.

Freeze-thaw cycling is less damaging here than for a structured peptide, since there is no fold to disrupt, but repeated cycling still concentrates solutes at the ice interface and still costs material to the walls of the vessel. The storage statement in the specification table is the product record for this material and should be checked against the documentation supplied with the lot.

Analytical notes specific to KPV

Analysis of a tripeptide is not simply an easier version of analysis of a larger peptide; it is harder in specific ways, and the standard documentation package is weaker here than it looks.

Intact mass by electrospray is weakly discriminating at this size. A tripeptide produces a low mass-to-charge ion, most likely singly protonated, in a region of the spectrum crowded with solvent clusters, salts, plasticizers and small organic contaminants. Many unrelated species land within a small window of the expected value. An intact mass consistent with the target is therefore a much weaker identity claim here than the same measurement would be for a thirty-residue peptide producing a distinctive multiply charged envelope. Tandem mass spectrometry, giving fragment ions that establish the residue order, is what actually confirms that the material is lysine-proline-valine and not some other arrangement of the same composition. For a three-residue peptide, sequence confirmation is not a luxury.

The acid-versus-amide question is also a mass spectrometry question, and it is an easy one to miss. The two forms differ by a small increment, well within the tolerance that a loosely specified method will accept as a match. If the distinction matters to the work, the mass tolerance has to be tight enough to resolve it and the reported figure has to be compared like for like, monoisotopic against monoisotopic or average against average.

Purity by area percent has a systematic problem here that deserves to be better known. Ultraviolet detection at around 214 nanometers responds principally to the peptide bond, so the response of a peptide scales roughly with how many peptide bonds it contains. In a mixture of very short species, area percent is therefore not proportional to molar or mass composition: a two-residue impurity is under-represented relative to a three-residue main component, and a longer impurity is over-represented. Area-percent purity in this size range should be read as a comparative number within one method, not as a composition.

There is no aromatic residue in the sequence, so there is no absorbance at 280 nanometers and no convenient spectrophotometric quantification. Concentration has to come from mass, from amino acid analysis or from a calibrated chromatographic method against a reference. Finally, the proline isomerization noted above can broaden or split peaks on a reversed-phase column, and that is a property of the molecule rather than evidence of an impure preparation.

Compounds researchers confuse with KPV

Questions specific to KPV